TGFBR1 and neoplasm: However, given the discovery of TGFβs in the late 1970s, progress to the clinic has been relatively slow, in part due to the discovery of cardiac toxicity in dogs after continuous administration of a small molecule inhibitor to TGFβR1 [253] and the complex roles of TGFβ itself in cancer progression acting either as a tumor suppressor or tumor promoter in a context dependent manner.